Patient characteristics
| Variables . | Patients . | ||
|---|---|---|---|
| No. (n = 25) . | % . | ||
| Age at infusion | Median (range) | 59 (20–69) | |
| Sex | Male | 14 | 56.0 |
| Female | 11 | 44.0 | |
| Disease | DLBCL | 25 | 100 |
| Disease status at infusion | PR | 4 | 16.0 |
| SD | 16 | 64.0 | |
| PD | 5 | 20.0 | |
| Pre–CAR-T regimens, numbers | Median (range) | 4 (3-12) | |
| History of auto-PBSCT | Yes | 9 | 36.0 |
| No | 16 | 64.0 | |
| Bridging chemotherapy before CAR-T infusion | Yes | 2 (R-CHASE) | 8.0 |
| No | 23 | 92.0 | |
| Duration | |||
| From Dx to Aph, d | Median (range) | 447 (128-3331) | |
| From Aph to infusion, d | Median (range) | 64 (47-83) | |
| From Dx to infusion, d | Median (range) | 515 (199-3413) | |
| Variables . | Patients . | ||
|---|---|---|---|
| No. (n = 25) . | % . | ||
| Age at infusion | Median (range) | 59 (20–69) | |
| Sex | Male | 14 | 56.0 |
| Female | 11 | 44.0 | |
| Disease | DLBCL | 25 | 100 |
| Disease status at infusion | PR | 4 | 16.0 |
| SD | 16 | 64.0 | |
| PD | 5 | 20.0 | |
| Pre–CAR-T regimens, numbers | Median (range) | 4 (3-12) | |
| History of auto-PBSCT | Yes | 9 | 36.0 |
| No | 16 | 64.0 | |
| Bridging chemotherapy before CAR-T infusion | Yes | 2 (R-CHASE) | 8.0 |
| No | 23 | 92.0 | |
| Duration | |||
| From Dx to Aph, d | Median (range) | 447 (128-3331) | |
| From Aph to infusion, d | Median (range) | 64 (47-83) | |
| From Dx to infusion, d | Median (range) | 515 (199-3413) | |
Aph, apheresis; Dx, diagnosis; PD, progressive disease; PR, partial remission; R-CHASE, rituximab, cyclophosphamide, cytosine arabinoside, etoposide, and dexamethasone; SD, stable disease.